key: cord-0736085-q5tqc9ey
authors: Erogul, Ozgur; Gobeka, Hamidu Hamisi; Dogan, Mustafa; Akdogan, Muberra; Balci, Aydin; Kasikci, Murat
title: Retinal microvascular morphology versus COVID-19: What to anticipate?
date: 2022-05-18
journal: Photodiagnosis Photodyn Ther
DOI: 10.1016/j.pdpdt.2022.102920
sha: 42775e1e1fd7ace6f553e2b8b3b6f668895b06aa
doc_id: 736085
cord_uid: q5tqc9ey

BACKGROUND: To investigate retinal microvascular morphological changes in previously COVID-19 infected patients using optical coherence tomography angiography (OCTA), and compare the findings to age- and gender-matched healthy subjects. METHODS: In this cross-sectional study, OCTA findings (6.0 × 6.0 mm scan size and scan quality index ≥7/10) from previously COVID-19 infected patients (group 1, 32 patients, 64 eyes) with ≥1 month of complete recovery were compared to healthy subjects (group 2, 33 subjects, 66 eyes) with no history of COVID-19 infection. A positive real-time reverse transcription-polymerase chain reaction test on a naso-pharyngeal swab sample confirmed the diagnosis. The AngioVueAnalytics, RTVue-XR 2017.1.0.155 software measured and recorded OCTA parameters. RESULTS: Group 1 had significantly lower superficial capillary plexus vessel densities in all foveal regions than group 2 (P<0.05). Foveal deep capillary plexus vessel density in group 1 was also significantly lower than in group 2 (P=0.009); however, no significant differences were found in other regions (P>0.05). All foveal avascular zone (FAZ) parameters were higher in group 1 than in group 2, with significant differences in FAZ area (P=0.019) and foveal vessel density 300 μm area around FAZ (P=0.035), but not FAZ perimeter (P=0.054). The outer retina and choriocapillaris flows were significantly lower in group 1 than in group 2 (P<0.05). CONCLUSIONS: Prior COVID-19 infection seems to be associated with significant changes in retinal microvascular density, as well as FAZ and flow parameters, which may be attributed to different pathogenic mechanisms that lead to SARS-CoV-2 infection, such as thrombotic microangiopathy and angiotensin-converting enzyme 2 disruption.

Since December 2019, the SARS-CoV-2 pandemic has caused widespread morbidity and mortality globally.

Further, since it was officially declared by the World Health Organization on March 11, 2020 , this pandemic has had a significant global impact, particularly on healthcare systems [1] . There is no effective treatment at the moment; however, several vaccines have been developed and are used solely for prevention. These vaccines are sometimes insufficient due to high mutation capacity of the coronavirus [2] .

Clinical manifestations and fatal outcomes of Coronavirus Disease 2019 (COVID- 19) , as well as reports on ocular symptoms are uncommon [3, 4] . This disease may be asymptomatic or affect multiple organs and tissues, including eyes. Many critically ill patients have been found to have an elevated coagulation state which may result in thromboembolic events and disseminated intravascular coagulation [5, 6] . Besides, endothelial damage has recently been reported to be widespread, resulting in ischemic damage to the microcirculatory system and subsequent functional problems in multiple organs [7, 8] . Despite the fact that the ocular effects of COVID -19 have not been thoroughly studied, many recent studies have reported non-specific retinal manifestations such as micro-hemorrhages, vasodilation, cotton wool spots, and flame hemorrhages [9] . Several studies have recently been conducted, in this context, to determine whether these findings are related to COVID-19 or are simply coincidental [10] .

Optical coherence tomography angiography (OCTA) is a novel, quick, and reliable non-invasive imaging technique that does not require dye injection. It can provide qualitative and quantitative features of retinochoroidal vascularization, as well as track changes in vascular perfusion in COVID-19 patients [11, 12] .

Aside from retinal vascular high-quality images, this technique can also be used to quantify parameters such as foveal avascular zone (FAZ) area and perifoveal capillary vascular density, as well as leak-free retinal ultrastructure [13] .

The aim of this study was to investigate retinal microvascular morphological changes in previously COVID-19 infected patients using OCTA, and compare the results to age-and gender-matched healthy subjects with no history of infection.

In this cross-sectional comparative single-centered study, we enrolled previously COVID-19 infected patients (group 1) with ≥1 month of recovery who had received treatment at the Afyonkarahisar Health Science University Hospital Chest Diseases Clinic and were consulted for ocular examination between 2020 and 2021. A positive real-time reverse transcription-polymerase chain reaction test on a naso-pharyngeal swab sample confirmed the diagnosis.

A control group (group 2) consisted of age-and gender-matched health subjects who visited our Ophthalmology Outpatient Clinic for a routine ophthalmological exam. These subjects had no history of contact with any COVID-19 infected patient or quarantine in the HES ('Hayat Eve Sığar'-Life Fits at Home) application developed by the country's health ministry, nor did they show any signs of having had a clinically active disease or complaints related to COVID-19 infection. Furthermore, their body temperatures were all found to be within the normal physiological range.

The study protocol adhered to the Declaration of Helsinki's ethical principles and was fully approved by the Afyonkarahisar Health Sciences University Ethics Committee. All participants gave written informed consent prior to participation.

Patients who had recovered from COVID-19 for ≥1 month, did not have any other ocular or systemic diseases, and did not smoke or drink alcohol on a regular basis, were eligible for the study. Both patients and healthy subjects with; (a) media opacities such as cornea diseases and defects, cataract, vitreous opacities, and other conditions that could impede high-quality imaging or lead to poor OCTA scan quality, (b) history of refractive and/or intraocular surgery, (c) prior ocular travma, particularly affecting the optic axis and posterior vascular system, (d) ocular diseases such as glaucoma, uveitis, and/or clinically significant retinal and optic nerve diseases, (e) any vasculopathy-related posterior ocular segment-involving systemic diseases such as diabetes, hypertension, and so on, (f) migraine, (g) pregnancy and/or breast-feeding, (h) autoimmune disorder, (i) spherical or cylindrical refractive error >±3 diopters (D), and/or an axial length >26.5 mm, (j) any topical or systemic medications, and (k) poor fixation during imaging procedure, were not eligible for the study.

All participants had a comprehensive ophthalmologic examination. This included measuring auto-refraction (Canon R-F10m; Canon Inc., Tokyo, Japan), best-corrected visual acuity in logarithm of the minimum angle of resolution (logMAR) and intraocular pressure (Goldmann; Haag-Streit AG, Köniz, Switzerland), as well as slitlamp biomicroscopy of the anterior and posterior segments before and after pupil dilation with tropicamide 1% and phenylephrine 10%.

The same technician performed all OCTA (Optovue, Inc., Fremont, California, USA) procedures using the same device. 304 evenly spaced sections along the x-axis, followed by the y-axis, in the 6.0x6.0 mm retinal area were scanned using the Angio Retina mode during B-scanning procedure. These sections were then stitched together to form 6.0x6.0 mm OCTA images. Using the 'Auto Adjust' mode, the axial length, refraction correction, and image polarization of the patient were all automatically adjusted during the procedure. The device's scan quality index, which is a score (1-10) assigned to OCTA images at the end of each acquisition by combining signal strength, ocular movements, and image focusing, was also used. Images with scan quality index ≤7/10 were omitted from the analysis. The procedure was then repeated several times until the recording quality was satisfactory. The eye tracking mode and motion correction technology significantly reduced ocular motion artifacts. A projection artifact removal system was used to remove any potential artifacts. The signal strength index was set to ≥40 as the cut-off value. All OCTA images were thoroughly assessed and approved by OE and HHG, as well as other authors (MD, MA, and MK), to achieve sufficient image quality and resolution.

Images with substantial motion artifacts that hampered the successful quantification of microvascular density were also discarded.

The AngioVueAnalytics, RTVue-XR 2017.1.0.155 software measured and recorded OCTA parameters such as vessel densities in superficial and deep retinal layers (superficial and deep capillary plexi), as well as FAZ area (mm 2 ), FAZ perimeter (mm), and foveal vessel density 300 μm area around FAZ (FD-300) (%). Microvascular flow parameters from the outer retina and choriocapillaris were also collected and analyzed.

We used the Statistical Package for the Social Sciences (SPSS Inc., version 23, Chicago, IL, USA) for data analysis. Descriptive statistical methods included number, percentage, mean, standard deviation, median, and interquartile range. Kolmogorov-Smirnov test was used to determine whether the data was normally distributed.

Independent sample T-test and Mann-Whitney U test were used to analyze the relationships between variables.

The Pearson correlation test was used to determine relationships of the variables. The results were assessed at a 95% confidence interval and a 5% significance level. Statistical significance was defined as P<0.05.

Group 1 had 32 (64 eyes) patients (female-to-male ratio: 71.90%:28.10%), while group 2 had 33 (66 eyes) health subjects (female-to-male ratio: 57.60%:42.40%). The mean age (P=0.088), best-corrected visual acuity (P=0.076), as well as intraocular pressure (P=0.067) did not differ significantly between the two groups. Five patients were outpatients with mild symptoms, meaning their medical treatment began in the hospital and continued at home, and 27 were hospitalized with moderate symptoms in the Chest Diseases clinic for an average of 5.20±2.20 days but did not experience acute respiratory distress disease. Patients with severe disease (acute respiratory distress admitted to the intensive care unit) were not included in the study. This information is also included elsewhere in the manuscript (Table 1) .

Compared to group 2, group 1 had significantly lower whole (P=0.011), foveal (P=0.014), parafoveal (P=0.011), and perifoveal (P=0.002) superficial capillary plexus vessel densities. Foveal deep capillary plexus vessel density in group 1 were also significantly lower than in group 2 (P=0.009). However, no significant differences were found in whole (P=0.177), parafoveal (P=0.153), and perifoveal (P=0.176) deep capillary plexus vessel densities. All FAZ parameters tended to be higher in group 1 than in group 2, with significant differences in FAZ area (P=0.019) and FD-300 (P=0.035), but not in FAZ perimeter (P=0.054) (Table 2, Figure   1(a-d) and (a*-d*) ).

Group 1 had significantly lower flow area in both outer retina (P=0.030) and choriocapillaris (P<0.05) than group 2 (Table 3, Figure 2(a, b) and (a*, b*))

We investigated retinal microvascular morphological changes in previously COVID-19 infected patients using OCTA, and compared the findings to age-and gender-matched healthy subjects. There was a fairly benign disease course in these patients, with only a few requiring hospitalization for an average of 5.20±2.20 days prior to getting discharged with full recovery. A post-treatment negative COVID test was confirmed by a PCR test twice in a 24-hour interval in outpatient patients prior to OCTA scanning. In hospitalized patients, after thrombotic and inflammatory markers such as D-Dimer, ferritin, fibrinogen, C-reactive protein, and pre-calcitonin returned to normal, the PCR test was repeated twice with a 24-hour interval to confirm negativity before discharge.

Overall, prior COVID-19 infection was associated with relatively lower mean retinal microvascular vessel densities. This was especially true for the whole, foveal, parafoveal, and perifoveal superficial capillary plexus vessel densities and foveal deep capillary plexus vessel density. The whole, parafoveal and perifoveal deep capillary plexus vessel densities were also lower in comparison to healthy subjects, despite not being statistically significant. These findings could be attributed to a number of pathogenic mechanisms that lead to SARS-CoV-2 infection, including both thrombotic microangiopathy and angiotensin-converting enzyme 2 disruption In our study, we performed a systematic analysis in previously COVID-19-infected patient population, comparing changes in retinal microvascular density to age-and gender-matched healthy subjects, and revealed, among other things, that COVID-19 infection was associated with signıficant enlargement of FAZ area and FD-300. The reasons for changes in retinal microvascular morphology discovered in our study are unclear. While direct coronavirus infection of the retina tissue is possible, secondary effects of infection cannot be ruled out either. Aggravation of underlying systemic diseases is also unimaginable, considering the relatively young age of the study patients and the absence of pre-existing pathological conditions.

In addition to changes in FAZ and microvascular flow parameters, we found that patients who had previously been infected with COVID-19 had lower microvascular density at least one month after full recovery.

Moreover, there was no decrease in best-corrected visual acuity in infected patients, and an extraocular examination was also unremarkable. We presume, consequently, that demonstrating the presence of retinal microvascular morphological changes in completely healthy asymptomatic eyes using OCTA is clinically valuable. It would also be interesting to know if these changes are related to retinal electrophysiological changes.

Most importantly, a longer period of observation may be necessary to determine if these subclinical microvascular morphological changes are to blame for the development of ischemic diseases and/or choroidal neovascularization.

Our study has some limitations. There were no data available for changes in microvascular density during the acute phase of COVID-19 infection. We measured microvascular densities of the foveal, parafoveal, and perifoveal regions. Measurements taken outside the fovea, however, were referred to as the outer retina, and were not divided into superior, inferior, nasal, and temporal quadrants. Fluorescein angiography was not used to investigate integrity of the retinal microvasculature, which appears to be one of the study limitations: however, as previously stated, we planned to investigate changes in microvascular density using a novel OCTA technique, which could also reveal retinochoroidal microvascular morphological changes without using contrast materials.

While all patients' ocular environments were clean, ocular surface irregularities may have hampered scan quality, and asymptomatic dry eye has been linked to COVID-19 [33, 34] . Additional validation of our findings may be needed to verify that decreased microvascular density in previously COVID-19-infected patients resulted from actual anatomical changes rather than artifacts. Moreover, since COVID-19 is a novel disease entity, longer follow-ups are clearly necessary. However, our study was a cross-sectional study, and OCTA measurements were only taken once for those who completely recovered from the disease. Thus, more long-term large scale clinical studies may be of merit to assess the relationship between OCTA parameters and the onset and duration of COVID-19 infection. Furthermore, longitudinal screening with re-imaging at predetermined intervals could provide important knowledge on the short-and long-term consequences of COVID-19 on the retinal microvasculature.

One of the advantages of our study is that all patients were free of COVID-19 infection and had no signs of ocular involvement, although some of them reported visual discomfort during active infection. In addition, compared to prior studies, more participants were evaluated. Measurement of FAZ parameters and microvascular flows in the outer retina and choriocapillaris may be another advantage of this study. The scan quality may have an effect on OCTA microvascular density analysis [35] . In this context, all participants included in the final analysis were subjected to a strict quality screening threshold ≥7/10.

Prior COVID-19 infection was associated with significant changes in retinal microvascular density, as well as FAZ and flow parameters. Despite the fact that we found significant OCTA changes in completely asymptomatic patients compared to healthy subjects, clinical significance of the visual symptoms observed during active infection remained uncertain. Potential effects of COVID-19 on the retina necessitate larger-scale studies that may better represent the ever-growing global population of COVID-19 infected patients.

All authors certify that they have no association or participation with any organization or individual with any financial interest or non-financial interest in the subject matter or materials discussed in this article.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all participants included in the study.

The manuscript contains all data. The datasets used and/or analyzed during the current study, however, are available upon reasonable request from the corresponding author. 

WHO Declares COVID-19 a Pandemic

What can we expect from first-generation COVID-19 vaccines? Lancet

Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear

Ocular manifestation, eye protection, and COVID-19

COVID-19 and its implications for thrombosis and anticoagulation

Coagulation abnormalities and thrombosis in patients with COVID-19

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19

An Update on COVID-19 Related Ophthalmic Manifestations

Retinal findings in patients with COVID-19: Results from the SERPICO-19 study

High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics

Retinal and choroidal vascular changes in coronary heart disease: an optical coherence tomography angiography study

Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study

Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep

Therapeutic targets of renin-angiotensin system in ocular disorders

The renin-angiotensin-aldosterone system and the eye in diabetes

Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye

Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily

The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?

-2 receptor: molecular mechanisms and potential therapeutic target

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Retinal findings in patients with COVID-19

Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication. Eye (Lond)

Unique case of central retinal artery occlusion secondary to COVID-19 disease

COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

Covid-Post-Acute Care Study Group. Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

Face Mask-Associated Ocular Irritation and Dryness

Evaluation of ocular symptoms and tropism of SARS

CoV-2 in patients confirmed with COVID-19

The Impact of

Deterministic Signal Loss on OCT Angiography Measurements. Transl Vis Sci Technol

0 mm scan size with scan quality index=9/10) segmented at the level of the superficial capillary plexus (a, a*), deep capillary plexus (b, b*), outer retina (c, c*), and choriocapillaris (d, d*) from a previously COVID-19 infected patient (letters without asterixis) and a healthy subject (letters with asterixis), respectively. Note the lower vessel densities in both superficial and deep capillary plexi in previously COVID-19 infected patients (a, b) compared to healthy controls (a*, b*). Previously COVID-19

The authors declare that they have received no public or private financial support or involvement in the products, methods, or materials mentioned in this manuscript, and there is no conflict of interest to disclose.

None